1 August 1991

Autoimmunity after Alpha-Interferon Therapy for Malignant Carcinoid Tumors

Publication: Annals of Internal Medicine
Volume 115, Number 3


Objective: To determine the incidence of autoantibodies and autoimmune disease and their influence on therapeutic results during alpha-interferon treatment in patients with malignant midgut carcinoid tumors.
Design: Consecutive sample of patients.
Setting: University hospital.
Patients: One hundred thirty-five patients (70 women, 65 men; median age, 59 years) with biopsyproven tumors, liver metastases, and no autoimmune disease.
Interventions: Leukocyte alpha-interferon (n = 88) or alpha-interferon 2b (n = 47) three times a week.
Main Outcome Measures: Signs and symptoms of autoimmune disease or development of autoantibodies to thyroid antigens, nuclear antigens, or gastric parietal cells. Tumor responses were determined by reduced liver metastases or reduced urinary 5-hydroxyindole acetic acid excretion, or both.
Results: Twenty-five patients (19%) developed the following autoimmune disorders after a median of 9 months of therapy: thyroid disease (n = 18), systemic lupus erythematosus (n = 1), pernicious anemia (n = 4), and vasculitis (n = 2). Antibodies to microsomal thyroid antigen or thyroglobulin were detected in 16 patients before therapy and in another 11 patients during therapy. Antinuclear antibodies were detected in 16 patients before and in another 19 patients during therapy. Clinical thyroid disease developed in more than 60% of patients who had or developed thyroid antibodies but in only 7% of initially autoantibody-negative patients. Autoimmunity did not correlate with objective tumor response.
Conclusion: Patients with malignant carcinoid tumors may develop autoimmune disease during alphainterferon therapy, especially when autoantibodies are present. They should therefore be monitored for autoimmunity, which does not appear, however, to influence tumor responses.

Get full access to this article

View all available purchase options and get full access to this article.


Isaacs A and Lindenmann J. Virus interference. I. The interferon. Proc Royal Soc B. 1957;147:258-67.
Härfast BHuddlestone JCasall PMerigan T, and Oldstone M. Interferon acts directly on human B lymphocytes to modulate immunoglobulin synthesis. J Immunol. 1981;127:2146-50.
Lindahl PLeary R, and Gresser I. Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes. Proc Natl Acad Sci USA. 1972;69:721-5.
Scultz RPapamatheakis J, and Chirgos M. Interferon: an inducer of macrophage activation by polyanions. Science. 1977;197:674-6.
Gidlund MÖrn AWigzell HSenik A, and Gresser I. Enhanced NK cell activity in mice injected with interferon and interferon inducers. Nature. 1978;273:759-61.
Grandér DÖberg KLundqvist MTiensuu JEEriksson B, and Einhorn S. Interferon-induced enhancement of 2′,5′-oligoadenylate synthetase in mid-gut carcinoid tumours. Lancet. 1990;2:337-40.
Strander H. Interferon Treatment of Human Neoplasia. In: Klein G, Weinhouse S, eds. Advances in Cancer Research, v. 46. London: Academic Press; 1986.
Öberg KFuna K, and Alm G. Effects of leucocyte interferon upon clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and the carcinoid syndrome. N Engl J Med. 1983;309:129-33.
Öberg KNorheim I, and Lind E. Treatment of malignant carcinoid tumours with human leukocyte interferon. Long-term results. Cancer Treat Rep. 1986;70:1297-304.
Öberg KAlm G, and Magnusson A. Treatment of malignant tumours with recombinant interferon alpha-2b (Introna); development of neutralizing interferon antibodies and possible loss of antitumour activity. J Natl Cancer Inst. 1989;81:531-35.
Pangalis G and Griva E. Recombinant alfa-2b-interferon therapy in untreated, stages A and B chronic lymphocytic leukemia. Cancer. 1988;61:869-72.
Fentiman IBalkwill FThomas BRusell MTodd I, and Bottazzo G. An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer. Eur J Cancer Clin Oncol. 1988;8:1299-303.
Burman PKarlsson AÖberg K, and Alm G. Autoimmune thyroid disease in interferon treated patients. Lancet. 1985;2:100-1.
Burman PTötterman HÖberg K, and Karlsson F. Thyroid autoimmunity in patients on long-term therapy with leucocyte derived lnterferon. J Clin Endocrinol Metabol. 1986;63:1086-90.
Abdi EBrien W, and Venner P. Auto-immune thrombocytopenia related to interferon therapy. Scand J Haematol. 1986;36:515-9.
Rönnblom LÖberg K, and Alm G. Possible induction of Systemic Lupus Erythematosus by interferon treatment in a patient with a malignant carcinoid tumour. Int J Med. 1990;227:207-10.
Karlsson-Parra ABurman PHagberg HÖberg KAlm G, and Klareskog I. Autoantibodies to epithelial cells in patients on long-term therapy with leucocyte-derived alpha-interferon (IFN-α). Clin Exp Immunol. 1990;81:72-5.
Cantell K and Hirvonen S. Large scale production of human leukocyte interferon containing 108 units per ml. J Gen Virol. 1978;39:541-3.
Tan MCohen A, and Fries J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-7.
Öberg KNorheim ILundqvist G, and Wide L. Cytotoxic treatment of patients with carcinoid tumors-response to streptozotocin alone or in combination with 5-fluorouracil. Acta Oncol. 1987;26:429-32.
Doniach DBottazzo G, and Drexhage H. The autoimmune endocrinopathies. In: Lachmann PJ, Peters DK, eds. Clinical Aspects of Immunology, v.2. Oxford: Blackwell Scientific Publications; 1982:903-37.
Tunbridge WEvered D, and Hall R. The spectrum of thyroid disease in a community: The Whickham survey. Clin Endocrinol. 1977;7:481-93.
Tunbridge WBrewis M, and French J. Natural history of autoimmune thyroiditis. Br Med J. 1981;282:258-62.
Lazarus JBurr MMcGregor AWeetman ALudgate MWoodhead J, and Hall R. The prevalence and progression of autoimmune thyroid disease in the elderly. Acta Endocrinol (Copenh). 1984;106:199-202.
Hawkins BDawkins R, and Burger H. Diagnostic significance of thyroid microsomal antibodies in randomly selected population. Lancet. 1980;2:1057-9.
BjØro TGaarder PSmeland E, and Kornstad L. Thyroid antibodies in blood donors: prevalence and clinical significance. Acta Endocrinol (Copenh). 1984;105:324-9.
Fessel G. Systemic lupus erythematosus in the community. Arch Intern Med. 1974;134:1027-35.
Fairley G. Autoantibodies in Malignant Disease. Br J Haematol. 1972;23(Suppl):231-4.
Nelson D. Autoantibodies in cancer patients. Pathology. 1977;9:155-60.
Hawkins B and Dawkins R. Autoantibodies in an Australian population. II. Association with HLA antigens. J Clin Lab Immunol. 1979;2:217-20.
Conlon KUrba WSmith JSteis RLongo D, and Clark J. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer. 1990;65:2237-42.
Hooks JMoutsopoulos HGeis SStahl NDecker J, and Notkins A. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med. 1979;301:5-8.
Hooks JJordan GCupps TMoutsopoulos HFauci A, and Notkins A. Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis. Arthritis Rheum. 1982;25:396-400.
Kim TKanayama YNegoro NOkamura MTakeda T, and Inoue T. Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol. 1987;70:562-9.
Bankhurst A. Interferons and systemic lupus erythematosus. J Rheumatol. 1987;14(Suppl 13):63-7.
Pak CMcArthur REun H, and Yoon J. Association of cytomegalovirus infection with autoimmune type 1 diabetes. Lancet. 1988;2:1-4.
Vento S and Eddlestone A. Immunological aspects of chronic active hepatitis. Clin Exp Immunol. 1987;68:225-32.
Ciampolillo AMirakian R, and Schulz T. Retrovirus-like sequences in Graves' disease: implications for human autoimmunity. Lancet. 1989;1:1096-1100.
Schattner ADuggan DNaparstek Y, and Schwartz R. Effects of alpha-interferon on the expression of a lupus idiotype in normal humans. Clin Immunol Immunopathol. 1986;38:327-36.
Revel M and Chebath J. Interferon activated genes. Trends Biol Sci. 1986;11:166-70.
De Vries R and Van Rood J. Immunobiology of HLA class-I and class-II molecules. Introduction. Prog Allergy. 1985;36:1-9.

Information & Authors


Published In

cover image Annals of Internal Medicine
Annals of Internal Medicine
Volume 115Number 31 August 1991
Pages: 178 - 183


Published in issue: 1 August 1991
Published online: 1 December 2008




Lars E. Rönnblom, MD, PhD
Gunnar V. Alm, MD, PhD
Kjell E. Öberg, MD, PhD
From Central Hospital, Boden, Sweden; and Uppsala University and Ludwig Institute for Cancer Research, Uppsala, Sweden. For current author addresses, see end of text.

Metrics & Citations



If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.


Download article citation data for:
Lars E. Rönnblom, Gunnar V. Alm, Kjell E. Öberg. Autoimmunity after Alpha-Interferon Therapy for Malignant Carcinoid Tumors. Ann Intern Med.1991;115:178-183. doi:10.7326/0003-4819-115-3-178

View More

Get Access

Login Options:

You will be redirected to to sign-in to Annals to complete your purchase.

Access to EPUBs and PDFs for FREE Annals content requires users to be registered and logged in. A subscription is not required. You can create a free account below or from the following link. You will be redirected to to create an account that will provide access to Annals. If you are accessing the Free Annals content via your institution's access, registration is not required.

Create your Free Account

You will be redirected to to create an account that will provide access to Annals.

View options


View PDF/ePub

Related in ACP Journals







Copy the content Link

Share on social media